ArticleBlood advances2026
Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractCytomegalovirus (CMV) reactivation reshapes immune reconstitution and remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). To understand the impact of asymptomatic CMV viremia on immune reconstitution, we profiled longitudinal blood samples (n = 32) from donor-recipient pairs before and after HSCT with single-cell RNA and T-cell receptor (TCR) sequencing for 3 months after transplantation. To analyze the development of antigen-specific T-cell responses in detail, we sorted and TCR-sequenced T cells specific to the immunodominant CMV epitope pp65. After HSCT, an early increase in CD14+ monocytes was observed, followed by expansion of T and natural killer (NK) cells. Persisting patient-cell chimerism was observed in the CD4+ T-cell fraction. CMV-specific T cells and CMV-associated adaptive NK cells matured slower in grafts from seronegative donors compared to those from seropositive donors. The early maturation of adaptive NK cells was markedly more rapid in patients with CMV-seropositive donors, with enhanced recall function; however, adaptive NK cell cytotoxicity was higher in patients with CMV-seronegative donors. Large oligoclonal CD8+ T-cell expansions against the immunodominant CMV pp65NLV epitope comprised up to 63.6% of the CD8+ T-cell repertoire, showing terminal maturation with upregulation of canonical NK cell receptors. Our study presents, to our knowledge, the first comprehensive single-cell transcriptomic characterization of adaptive immune recovery after allogeneic HSCT, with a particular focus on CMV reactivation. Our findings highlight the impact of donor CMV serostatus on immune maturation in recipients with CMV reactivation, which may help predict the timing of immune reconstitution and inform strategies for management of posttransplant complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.